Translate page

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML patient cases here. Clinicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("+ NEW TOPIC" button below).

Each clinical case will be forwarded to the iCMLf expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are only accepted from clinicians. If individual patients have a specific question we encourage them to contact their healthcare provider.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

Three-way Philadelphia chromosome

  • Nasir Ahmad
  • Nasir Ahmad's Avatar Topic Author
1 month 1 day ago #1729 by Nasir Ahmad
Three-way Philadelphia chromosome was created by Nasir Ahmad
Respected all! I am relatively new and has worked in lab mostly. I found a case three-way Philadelphia translocation 46,xy, t (3;9;22) (p21;q34;q11.2). He has been prescribed imatinib 400 mg OD and is doing well apparently.

I want to know if he needs to switch to nilotinib, is there any guidelines showing which drug should the patient use?

Nasir
PhD research student
  • Susan Branford
  • Susan Branford's Avatar Topic Author
1 month 1 day ago #1730 by Susan Branford
Replied by Susan Branford on topic Three-way Philadelphia chromosome
The MD Anderson published their data in 2004 that assessed the results of imatinib for patients with variant Philadelphia chromosome (El-Zimaity et al, Br J Haematol, 2004:125;187-95). In a multivariate analysis, the variant Ph had no impact in response rate, overall survival or duration of response.

ORIGINAL CASE:
I found a case three-way Philadelphia translocation 46,xy, t (3;9;22) (p21;q34;q11.2). He has been prescribed imatinib 400 mg OD and is doing well apparently.

I want to know if he needs to switch to nilotinib, is there any guidelines showing which drug should the patient use?
Moderators: Melissa Davis-Bishop